Efmirenpase alfa

Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1) . Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research[1][2].

Product Specifications

CAS Number

[2770242-54-9]

Product Name Alternative

INZ-701

UNSPSC

12352100

Target

Phosphodiesterase (PDE)

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Cardiovascular Disease

References & Citations

[1]Chunn LM, et al. Estimation of ENPP1 deficiency genetic prevalence using a comprehensive literature review and population databases. Orphanet J Rare Dis. 2022 Dec 2;17 (1) :421. |[2]Internacionales D C. International Nonproprietary Names for Pharmaceutical Substances (INN) [J]. WHO Drug Information, 2025, 39 (2) .